In a subcutaneous tumor model, tumors with elevated CRSP8 expression demonstrated a more favorable response to the combined treatment of orlistat and anti-PD-L1 therapy, compared to anti-PD-L1 therapy alone (Fig. 8B-C). This evidence concerns the gene CD274 and neoplasm.